Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Dec;83(12):1715–1721. doi: 10.1054/bjoc.2000.1506

Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells

G B Ragnarsson 1, E K Mikaelsdottir 1, H Vidarsson 1, J G Jónasson 2,3, K Ólafsdóttir 2, K Kristjánsdóttir 3, J Kjartansson 4, H M Ögmundsdóttir 1,3, T Rafnar 1,3
PMCID: PMC2363445  PMID: 11104571

Abstract

Fas ligand (FasL) is expressed on some cancers and may play a role in the immune evasion of the tumour. We used immuno-histochemistry to study the expression of Fas and FasL in tissue samples from breast cancer patients, as well as normal breast tissue. Our results show that Fas and FasL are co-expressed both in normal tissue and in breast tumours. Fas and FasL mRNA were expressed in fresh normal and malignant breast tissue, as well as cultured breast epithelium and breast cancer cell lines. Flow cytometry analysis of live cells failed to detect FasL on the surface of normal or malignant breast cells; however, both stained positive for FasL after permeabilization. Fas was detected on the surface of normal breast cells and T47D and MCF-10A cell lines but only intracellularly in other breast cell lines tested. Neither normal breast epithelium nor breast cell lines induced Fas-dependent apoptosis in Jurkat cells. Finally, 20 tumour samples were stained for apoptosis. Few apoptotic cells were detected and there was no increase in apoptotic cells on the borders between tumour cells and lymphocytes. We conclude that FasL is expressed intracellularly in both normal and malignant breast epithelium and unlikely to be important for the immune evasion of breast tumours. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: Fas, apoptosis, breast neoplasm, tumour infiltrating lymphocytes, CD95, FasL

Full Text

The Full Text of this article is available as a PDF (239.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baskar S., Clements V. K., Glimcher L. H., Nabavi N., Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol. 1996 May 15;156(10):3821–3827. [PubMed] [Google Scholar]
  2. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. C. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19;377(6550):630–632. doi: 10.1038/377630a0. [DOI] [PubMed] [Google Scholar]
  3. Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998 Jun 1;160(11):5669–5675. [PubMed] [Google Scholar]
  4. Chappell D. B., Zaks T. Z., Rosenberg S. A., Restifo N. P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 1999 Jan 1;59(1):59–62. [PMC free article] [PubMed] [Google Scholar]
  5. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J. Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997 Oct;18(10):493–497. doi: 10.1016/s0167-5699(97)01115-8. [DOI] [PubMed] [Google Scholar]
  6. Garrido F., Ruiz-Cabello F., Cabrera T., Pérez-Villar J. J., López-Botet M., Duggan-Keen M., Stern P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997 Feb;18(2):89–95. doi: 10.1016/s0167-5699(96)10075-x. [DOI] [PubMed] [Google Scholar]
  7. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995 Nov 17;270(5239):1189–1192. doi: 10.1126/science.270.5239.1189. [DOI] [PubMed] [Google Scholar]
  8. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  9. Iwamoto M., Koji T., Makiyama K., Kobayashi N., Nakane P. K. Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol. 1996 Oct;180(2):152–159. doi: 10.1002/(SICI)1096-9896(199610)180:2<152::AID-PATH649>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  10. Jerome K. R., Barnd D. L., Bendt K. M., Boyer C. M., Taylor-Papadimitriou J., McKenzie I. F., Bast R. C., Jr, Finn O. J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991 Jun 1;51(11):2908–2916. [PubMed] [Google Scholar]
  11. Kontny H. U., Lehrnbecher T. M., Chanock S. J., Mackall C. L. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res. 1998 Dec 15;58(24):5842–5849. [PubMed] [Google Scholar]
  12. Leithäuser F., Dhein J., Mechtersheimer G., Koretz K., Brüderlein S., Henne C., Schmidt A., Debatin K. M., Krammer P. H., Möller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993 Oct;69(4):415–429. [PubMed] [Google Scholar]
  13. Nagata S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–365. doi: 10.1016/s0092-8674(00)81874-7. [DOI] [PubMed] [Google Scholar]
  14. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A. Human lung carcinomas express Fas ligand. Cancer Res. 1997 Mar 15;57(6):1007–1012. [PubMed] [Google Scholar]
  15. O'Connell J., Bennett M. W., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999 Jan;20(1):46–52. doi: 10.1016/s0167-5699(98)01382-6. [DOI] [PubMed] [Google Scholar]
  16. O'Connell J., Bennett M. W., O'Sullivan G. C., O'Callaghan J., Collins J. K., Shanahan F. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol. 1999 Jul;6(4):457–463. doi: 10.1128/cdli.6.4.457-463.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. O'Sullivan C., Lewis C. E. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 1994 Mar;172(3):229–235. doi: 10.1002/path.1711720302. [DOI] [PubMed] [Google Scholar]
  18. Rensing-Ehl A., Frei K., Flury R., Matiba B., Mariani S. M., Weller M., Aebischer P., Krammer P. H., Fontana A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995 Aug;25(8):2253–2258. doi: 10.1002/eji.1830250821. [DOI] [PubMed] [Google Scholar]
  19. Smith D., Sieg S., Kaplan D. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol. 1998 May 1;160(9):4159–4160. [PubMed] [Google Scholar]
  20. Srivastava M. D., Srivastava B. I. Soluble Fas and soluble Fas ligand proteins in human milk: possible significance in the development of immunological tolerance. Scand J Immunol. 1999 Jan;49(1):51–54. doi: 10.1046/j.1365-3083.1999.00464.x. [DOI] [PubMed] [Google Scholar]
  21. Stewart T. H., Tsai S. C. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis. 1993 Jul;11(4):295–305. doi: 10.1007/BF00058049. [DOI] [PubMed] [Google Scholar]
  22. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  23. Whiteside T. L., Miescher S., Hurlimann J., Moretta L., von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23(3):169–178. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Xerri L., Devilard E., Hassoun J., Mawas C., Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol. 1997 Apr;50(2):87–91. doi: 10.1136/mp.50.2.87. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES